Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 17/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | TLR2 | O60603 | 1/20 | 0.50 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.50 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | PRKDC | P78527 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16385983 | 0.89 | ERN1 (0.67) | ERN1KDM4EALDH1A1TSHRTDP1 | |
| SCHEMBL5144957 | 0.85 | ERN1 (0.59) | ERN1KDM4EALDH1A1TSHRTDP1 | |
| SCHEMBL16093496 | 0.85 | ERN1 (0.62) | ERN1KDM4EALDH1A1TSHRTDP1 | |
| SCHEMBL16093499 | 0.85 | ERN1 (0.62) | ERN1KDM4EALDH1A1TSHRTDP1 | |
| SCHEMBL11999813 | 0.84 | ERN1 (0.61) | ERN1KDM4EALDH1A1TSHRTDP1 | |
| SCHEMBL13079432 | 0.82 | ERN1 (0.56) | ERN1TDP1TLR2TLR1TLR6 | |
| SCHEMBL3751505 | 0.82 | ALDH1A1 (0.59) | ERN1KDM4EALDH1A1TSHRTDP1 | |
| SCHEMBL28020131 | 0.81 | ERN1 (0.62) | ERN1KDM4EALDH1A1TSHRTDP1 | |
| SCHEMBL9860690 | 0.80 | ERN1 (0.57) | ERN1KDM4EALDH1A1TSHRTDP1 | |
| SCHEMBL12766804 | 0.80 | ERN1 (1.00) | ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760773-B2 | Small molecule drug conjugates of gemcitabine monophosphate | MAVERIX ONCOLOGY, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20210380626-A1 | NOVEL SMALL MOLECULE DRUG CONJUGATES OF GEMCITABINE DERIVATIVES | MAVERIX ONCOLOGY, INC. | 2021-12-09 | — | — | US | disclosed |
| US-20210040136-A1 | SMALL MOLECULE DRUG CONJUGATES OF GEMCITABINE MONOPHOSPHATE | MAVERIX ONCOLOGY, INC. | 2021-02-11 | — | — | US | disclosed |
| WO-2019152955-A9 | SMALL MOLECULE DRUG CONJUGATES OF GEMCITABINE MONOPHOSPHATE | EVERETT STEVEN ALBERT (US) | 2020-08-13 | — | — | WO | disclosed |
| WO-2019152911-A1 | NOVEL SMALL MOLECULE DRUG CONJUGATES OF GEMCITABINE DERIVATIVES | EVERETT STEVEN ALBERT (US) | 2019-08-08 | — | — | WO | disclosed |
| WO-2019152955-A1 | SMALL MOLECULE DRUG CONJUGATES OF GEMCITABINE MONOPHOSPHATE | EVERETT STEVEN ALBERT (US) | 2019-08-08 | — | — | WO | disclosed |
| CN-103896895-A | Method for preparing coumarin derivative | UNIV ZHEJIANG TECHNOLOGY | 2014-07-02 | — | — | CN | disclosed |
| CN-1117093-C | Pyrazolo [1, 5-a ] pyrimidine derivatives, their use and compositions | OTSUKA PHARMA CO LTD (JP) | 2003-08-06 | — | — | CN | disclosed |
| EP-1081149-B1 | PYRAZOLO 1,5-a]PYRIMIDINE DERIVATIVES | OTSUKA PHARMA CO LTD (JP) | 2003-04-02 | — | — | EP | disclosed |
| US-6372749-B1 | PHARMACOLOGICAL EFFECTS SUCH AS ANALGESIC ACTION, INHIBITORY EFFECT ON NITROGEN MONOXIDE SYNTHETASE AND THE LIKE AND ARE USEFUL AS ANALGESICS. | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2002-04-16 | — | — | US | disclosed |
| CN-1299362-A | Pyrazolo [1,5-a] pyrimidine derivatives | OTSUKA PHARMA CO LTD (JP) | 2001-06-13 | — | — | CN | disclosed |
| EP-1081149-A1 | PYRAZOLO 1,5-a]PYRIMIDINE DERIVATIVES | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2001-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210380626-A1 | NOVEL SMALL MOLECULE DRUG CONJUGATES OF GEMCITABINE DERIVATIVES | ZYX, KRAS, SLC7A5 | ERN1 2698/4885KDM4E 1495/4885ALDH1A1 3278/4885 |
| US-11760773-B2 | Small molecule drug conjugates of gemcitabine monophosphate | ZYX, SLC7A5, GMPS | ERN1 2708/4885KDM4E 1764/4885ALDH1A1 2475/4885 |
| US-20210040136-A1 | SMALL MOLECULE DRUG CONJUGATES OF GEMCITABINE MONOPHOSPHATE | ZYX, SLC7A5, GMPS | ERN1 2775/4885KDM4E 1832/4885ALDH1A1 2511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.